Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer

This study aims to evaluate the feasibility of a magnetic resonance (MR) automatic method for quantitative assessment of the percentage of fibrosis developed within locally advanced rectal cancers (LARC) after neoadjuvant radiochemotherapy (RCT). A total of 65 patients were enrolled in the study and MR studies were performed on 3.0 Tesla scanner; patients were followed-up for 30 months. The percentage of fibrosis was quantified on T2-weighted images, using automatic K-Means clustering algorithm. According to the percentage of fibrosis, an optimal cut-off point for separating patients into favorable and unfavorable pathologic response groups was identified by ROC analysis and tumor regression grade (MR-TRG) classes were determined and compared to histopathologic TRG. An optimal cut-off point of 81% of fibrosis was identified to differentiate between favorable and unfavorable pathologic response groups resulting in a sensitivity of 78.26% and a specificity of 97.62% for the identification of complete responders (CRs). Interobserver agreement was good (0.85). The agreement between P-TRG and MR-TRG was excellent (0.923). Significant differences in terms of overall survival (OS) and disease free survival (DFS) were found between favorable and unfavorable pathologic response groups. The automatic quantification of fibrosis determined by MR is feasible and reproducible.

[1]  Stuart A. Taylor,et al.  Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting , 2018, European Radiology.

[2]  R. Vera,et al.  Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease‐free survival after preoperative radiochemotherapy for advanced rectal cancer , 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[3]  L. Påhlman,et al.  Is radiochemotherapy necessary in the treatment of rectal cancer? , 1998, European journal of cancer.

[4]  A. O'Grady,et al.  The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[5]  D. Aust,et al.  Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. , 2016, European journal of cancer.

[6]  P. Delrio,et al.  Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile , 2016, Oncotarget.

[7]  J. Monson,et al.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial , 2009, The Lancet.

[8]  L. Stassen,et al.  Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment , 2015, Annals of Surgical Oncology.

[9]  Stuart A. Taylor,et al.  Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting , 2017, European Radiology.

[10]  P. Delrio,et al.  Standardized Index of Shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC , 2015, European Radiology.

[11]  T L Chenevert,et al.  Utility of the K-Means Clustering Algorithm in Differentiating Apparent Diffusion Coefficient Values of Benign and Malignant Neck Pathologies , 2010, American Journal of Neuroradiology.

[12]  Ich Harmonised,et al.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .

[13]  Ivana Blažić,et al.  MRI for evaluation of treatment response in rectal cancer. , 2016, The British journal of radiology.

[14]  O. C. S. Mrcs,et al.  MRI Predictive Factors for Long-Term Outcomes of Low Rectal Tumours , 2011, Annals of Surgical Oncology.

[15]  P. Delrio,et al.  MRI for Assessing Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer Using DCE-MR and DW-MR Data Sets: A Preliminary Report , 2015, BioMed research international.

[16]  R. Perez,et al.  Nonoperative management of rectal cancer: identifying the ideal patients. , 2015, Hematology/oncology clinics of North America.

[17]  G. Brandi,et al.  Neoadjuvant Treatment in Rectal Cancer: Actual Status , 2011, Chemotherapy research and practice.

[18]  P. Tekkis,et al.  Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG). , 2016, Clinical radiology.

[19]  Nickolas Papanikolaou,et al.  Role of Magnetic Resonance Imaging in Primary Rectal Cancer-Standard Protocol and Beyond. , 2016, Seminars in ultrasound, CT, and MR.

[20]  V. Tombolini,et al.  Neoadjuvant-intensified treatment for rectal cancer: time to change? , 2013, World journal of gastroenterology.

[21]  Ivan Cecconello,et al.  Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer , 2016, Diseases of the colon and rectum.

[22]  Gina Brown,et al.  Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy , 2016, Diseases of the colon and rectum.

[23]  Rainer Fietkau,et al.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Marijnen,et al.  The role of radiotherapy in rectal cancer. , 2001, European journal of cancer.

[25]  P. D. Peppercorn,et al.  Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study , 2006, BMJ : British Medical Journal.

[26]  S. Andreola,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1998, International Journal of Colorectal Disease.

[27]  F. Taylor,et al.  MRI after treatment of locally advanced rectal cancer: how to report tumor response--the MERCURY experience. , 2012, AJR. American journal of roentgenology.

[28]  Angelita Habr-Gama,et al.  Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management? , 2013, Diseases of the colon and rectum.

[29]  S. Ricci,et al.  Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer , 2012, Annals of Surgical Oncology.

[30]  S. Balyasnikova,et al.  Imaging Advances in Colorectal Cancer , 2016, Current Colorectal Cancer Reports.

[31]  M. Lahaye,et al.  Accuracy of MRI in Restaging Locally Advanced Rectal Cancer After Preoperative Chemoradiation , 2017, Diseases of the colon and rectum.

[32]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[33]  Gina Brown,et al.  Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales , 2016, World journal of gastroenterology.

[34]  Sang Woo Lim,et al.  Coloproctology Clinical Significance of Tumor Regression Grade in Rectal Cancer with Preoperative Chemoradiotherapy , 2022 .